Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD
PositiveFinancial Markets

Arcutis Biotherapeutics has reached a significant milestone as its stock hits a 52-week high of $21.3. This achievement reflects growing investor confidence in the company's innovative dermatological treatments and its potential for future growth. As the biotech sector continues to evolve, Arcutis's performance could signal positive trends for similar companies in the industry.
— Curated by the World Pulse Now AI Editorial System